IASLC TTLC 2024 | Targeting NTRK and NRG in lung cancer treatment

Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, explains the use of targeted therapies such as tyrosine kinase inhibitors (TKIs) and tropomyosin receptor kinase (TRK) inhibitors for non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase (NTRK) or neuregulin-1 (NRG1) gene fusions. NTRK and NRG fusions are rare oncogenic drivers and there are currently a few FDA-approved therapies for NTRK-positive NSCLC, such as larotrectinib and entrectinib, which are both TRK inhibitors. Toxicity of these treatments primarily affects the central nervous system (CNS), presenting as cognitive impairment, sleeping difficulties, or mood disturbances. Resistance to these treatments can occur, though on-target resistance mechanisms are typically treatable with repotrectinib. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.